Analysts at Jefferies issued a note Friday morning saying they see "good interest" for use of MannKind's Afrezza drug.
Afrezza, the company's signature drug, is an inhalable product to treat diabetes.
The firm reiterated its "buy" rating with a price target of $9 following its recent Afrezza survey.
Jefferies surveyed 56 endocrinologists and primary care physicians about their expected use of Afrezza for diabetes.
The firm said in a note,
In screening physicians, we found that 35% did not know about Afrezza. Those that did, however, expected to use Afrezza more frequently than we had expected, especially among type 1 diabetics.
MannKind is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. The company is based in Valencia, Calif.